Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma
- PMID: 11948229
- DOI: 10.1093/jjco/hyf011
Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma
Abstract
Background: Measurement of carcinoembryonic antigen (CEA) has been widely applied to detect recurrence, especially of colorectal carcinoma. The validity however, is still controversial. We investigated serial changes in CEA values to calculate whether the CEA doubling time and half-life time could predict metastatic progression or prognosis in colorectal carcinoma.
Methods: Pre- and post-operative serial serum CEA contents were determined in 22 cases of colorectal cancer with or without metastasis. CEA values were determined by enzyme immunoassay (EIA). Patients were assigned depending upon survival time (within vs. more than 18 months after primary resection) for assessment of CEA doubling time. From the gradient of the semi-logarithmic CEA graph, the preoperative doubling time was calculated and the postoperative half-life time was estimated according to the diagnosis of metastases within 2 years after primary resection [metastasis (+) or (-)].
Results: In spite of the effect of curative re-operation of metastatic lesions or of postoperative adjuvant chemotherapy, the CEA doubling time of the groups showed a relation with prognosis (p = 0.045, Student's t-test) when the patients were divided into >18 and < or =18 months survival time. The CEA half-life time of the groups without overlooked metastases was statistically longer than those with (mean +/- SD 8.01 +/- 2.07 and 4.33 +/- 1.11, respectively, p < 0.01, one-factor ANOVA test). Clearance (k) showed a significant difference between the groups (p < 0.001, Student's t-test).
Conclusion: The CEA doubling time appeared to be a less independent prognostic factor, whereas prolongation of the CEA half-life time might potentially suggest the existence of overlooked synchronous metastases from colorectal carcinoma.
Similar articles
-
Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.Jpn J Clin Oncol. 2000 Jan;30(1):12-6. doi: 10.1093/jjco/hyd003. Jpn J Clin Oncol. 2000. PMID: 10770562
-
Comparison of doubling times of serum carcinoembryonic antigen produced by various metastatic lesions in recurrent gastric and colorectal carcinomas.Cancer. 1993 Jun 15;71(12):4055-9. doi: 10.1002/1097-0142(19930615)71:12<4055::aid-cncr2820711241>3.0.co;2-q. Cancer. 1993. PMID: 8508370
-
Distributions in CEA doubling time differ in patients with recurrent colorectal carcinomas.Hepatogastroenterology. 2004 Jan-Feb;51(55):147-51. Hepatogastroenterology. 2004. PMID: 15011851
-
[Surgical treatment of pulmonary metastasis of colorectal cancer. Prognostic survival factors].Presse Med. 1998 May 16;27(18):885-8. Presse Med. 1998. PMID: 9767880 Review. French.
-
The role of carcinoembryonic antigen monitoring in management of colorectal cancer.Curr Oncol Rep. 1999;1(2):168-72. doi: 10.1007/s11912-999-0029-z. Curr Oncol Rep. 1999. PMID: 11122815 Review.
Cited by
-
Prognostic significance of the postoperative/preoperative serum CEA level ratio in patients with solitary adrenal metastasis from lung cancer.Mol Clin Oncol. 2022 Jan;16(1):10. doi: 10.3892/mco.2021.2443. Epub 2021 Nov 14. Mol Clin Oncol. 2022. PMID: 34881030 Free PMC article.
-
Impact of the post/preoperative serum CEA ratio on the survival of patients with rectal cancer.Surg Today. 2014 Nov;44(11):2106-15. doi: 10.1007/s00595-014-0852-1. Epub 2014 Feb 7. Surg Today. 2014. PMID: 24504847
-
The feasibility of using mutation detection in ctDNA to assess tumor dynamics.Int J Cancer. 2017 Jun 15;140(12):2642-2647. doi: 10.1002/ijc.30620. Epub 2017 Mar 2. Int J Cancer. 2017. PMID: 28124376 Free PMC article. Review.
-
Clinical utility of the carcinoembryonic antigen level in patients with stage III colon cancer after surgery and adjuvant chemotherapy.Surg Today. 2024 Jul;54(7):692-701. doi: 10.1007/s00595-023-02779-6. Epub 2023 Dec 16. Surg Today. 2024. PMID: 38103076
-
Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update.Cancer Manag Res. 2024 Apr 8;16:299-310. doi: 10.2147/CMAR.S440477. eCollection 2024. Cancer Manag Res. 2024. PMID: 38617188 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical